09.00 - 12.00
Beyond Antibodies: Biologic Drug Development With Genetically-Encodable Constrained Peptides
Antibodies make great drugs, but they’re not a one-size-fits-all solution. Genetically-encodable constrained peptides are an alternative scaffold that can be useful for applications where antibodies are not ideal, e.g. gastrointestinal, pulmonary, topical.
This session will explore:
For which diseases are constrained peptides suitable as therapeutics, and what are the advantages over small molecules and antibodies?
Interfacing genetically-encodable peptides with synthetic biology: what are the opportunities and roadblocks?
What are the challenges of a computational approach to the design of constrained peptides, and how can these be overcome?
Christopher D. Bahl
Head of Protein Design,
Institute for Protein Innovation
Workshop B Tuesday 13 November 2018
13.00 - 16.00
Using Computational Tools To Design & Optimize Novel Biologics
Engage directly with protein and cell engineers to address how to create novel therapeutics that go beyond monoclonal antibodies and naturally occurring proteins.
Attendees will discuss:
How to define product profiles that can be achieved by rational design
How to design useful starting entities
Tissue targeting of therapeutic cells and proteins to minimize side effects
Senior Staff Scientist
Wyss Institute, Harvard University
Crowne Plaza Boston - Woburn
15 Middlesex Canal Park Dr
Hanson Wade's goal is to accelerate progress within organisations and across industries. Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers.